Division of Clinical Chemistry, C1:74, Department of Laboratory Medicine, Karolinska University Hospital Huddinge, 141 86, Stockholm, Sweden.
Metabolism Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Drugs. 2017 Oct;77(15):1613-1621. doi: 10.1007/s40265-017-0791-4.
Thyroid hormones have important effects on cellular development, growth, and metabolism and are necessary for the healthy function of almost all tissues. Hyperthyroid patients with excess thyroid hormone levels experience tachycardia, fatigue, muscle wasting, and osteoporosis. However, although high thyroid hormone levels have adverse effects, efforts have been made to harness the beneficial effects, such as reduced serum low-density lipoprotein (LDL) cholesterol levels, elevated basal metabolic rate, and weight loss. Thyroid hormones interact with nuclear thyroid hormone receptors (TRs), and cholesterol levels are reduced through TRβ, whereas extrahepatic adverse actions are primarily connected to TRα. Thus, to develop a useful compound for clinical use, efforts have been focusing on developing compounds with isomer-specific functions based on the structure of thyroid hormones, i.e., thyromimetics that are liver and/or TRβ specific. In this short review, we discuss the development of the early thyromimetics that enabled, through modern molecular techniques, the progress towards improved design of TRβ-selective thyromimetics. We also address the early promise shown in human clinical trials and the current status of these drugs and other emerging compounds.
甲状腺激素对细胞的发育、生长和代谢有重要影响,是几乎所有组织正常功能所必需的。甲状腺激素水平过高的甲亢患者会出现心动过速、疲劳、肌肉减少和骨质疏松。然而,尽管高甲状腺激素水平有不良影响,但人们已经努力利用其有益作用,如降低血清低密度脂蛋白(LDL)胆固醇水平、提高基础代谢率和减轻体重。甲状腺激素与核甲状腺激素受体(TR)相互作用,胆固醇水平通过 TRβ 降低,而肝外不良作用主要与 TRα 有关。因此,为了开发一种用于临床的有用化合物,人们一直在努力开发基于甲状腺激素结构的具有异构体特异性功能的化合物,即肝和/或 TRβ 特异性的拟甲状腺素。在这篇简短的综述中,我们讨论了早期拟甲状腺素的发展,这些化合物通过现代分子技术,促进了 TRβ 选择性拟甲状腺素的设计改进。我们还讨论了在人类临床试验中显示出的早期前景以及这些药物和其他新兴化合物的现状。